
|Articles|May 15, 2005
Site-active steroid provides symptomatic relief for patients with dry eye disease
Miami—Anti-inflammatory treatment using loteprednol etabonate suspension 0.2% (Alrex, Bausch & Lomb) appears to offer a safe and useful option for symptomatic relief in patients with dry eye, according to Roberto Beraja, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
News from Orlando: AAO 2025 highlights research across all areas of eyecare
2
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
3
AAO 2025: Glaucoma laser surgery with Joel S. Schuman, MD, FACS
4
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
5